Mr. Aaron Zhou's practice focuses on cross-border and domestic mergers and acquisitions, private equity investment, venture capital investment, pharmaceutical/healthcare-related (BD) transactions, foreign direct investment (FDI), joint ventures, and general corporate matters. Mr. Zhou's practice covers a variety of industries, including technology, pharmaceutical, medical device, the Internet, telecommunications, healthcare management, insurance, clean energy, natural resources, finance, and culture and entertainment. Mr. Zhou has represented many renowned multinational and PRC companies in their cross-border and domestic merger and acquisition transactions and has acted for many foreign and domestic funds and companies in their private equity financing and venture capital investment projects. He provides a full range of legal services in these transactions and projects, including deal structuring, legal due diligence, drafting and reviewing transaction documents, and leading negotiations. Mr. Zhou has helped many multinational and PRC pharmaceutical and medical device companies in out-license/in-license for the commercialization, development and manufacturing of pharmaceutical products and medical devices, sale and purchase of healthcare-related assets and businesses, research collaboration and manufacturing services agreements, supply agreements, CSO agreements, as well as distribution transactions. He has also helped PRC companies in their IPOs and listings on overseas stock exchanges, U.S. dollar and euro bond issuances, and listed company restructurings. In addition, Mr. Zhou is well-experienced in handling general corporate and compliance matters.
Mr. Zhou has over 20 years' legal experience, including five years at a top-five Wall Street law firm, three years as the Asia Pacific legal head of a Fortune Global 50 company, and legal counsel for the healthcare business of a Fortune Global 500 company. Mr. Zhou is a current member of the Equity Investment Committee as well as the Foreign Investment and Opening-up Committee of the Insurance Asset Management Association of China.
Mr. Zhou has been recognized as a Leading Lawyer in Corporate/M&A and Healthcare by authoritative international legal rankings, such as Chambers and Partners, The Legal 500, IFLR1000 and Asian Legal Business (ALB). Mr. Zhou has been selected as a leading lawyer in Corporate/M&A by Chambers Global (2023-2024), a leading lawyer in Healthcare and Corporate/M&A by Chambers Greater China (2022-2024), a Next Generation Partner in Corporate and M&A (2020-2024), a Next Generation Partner in Life Science & Healthcare (2022-2024) and a Recommended Lawyer in Corporate and M&A (2019) by Legal 500 Asia Pacific, a Notable Practitioner in Corporate and M&A, Restructuring and Insolvency by IFLR1000 (2022-2023), and a Top 15 Rising Lawyer by Asian Legal Business (ALB) (2018), and was shortlisted as Beijing M&A Lawyer of the Year by IFLR1000 China Awards (2022-2023).
